key: cord-0889305-ftl4v9yz
authors: Morris, Stephen R; Natori, Yoichiro; Salguero, Douglas; Mantero, Alejandro; Ma, Ruixuan; de Lima Corvino, Daniela F; Fernandez, Anmary; Lazo, Alex; Vu, Christine A; Bjork, Lauren; Serota, David; Quevedo, Jennifer; Vega, Ana; Maxam, Meshell; DeRonde, Kailynn; Barreiro, Pablo; Raccamarich, Patricia; Romero Alvarez, Maria; Skiada, Dimitra; Balan, Shuba; Ramanathan, Maya; Holt, Gregory; Gonzales-Zamora, Jose; Baracco, Gio J; Doblecki-Lewis, Susanne; Abbo, Lilian M; Lichtenberger, Paola N; Alcaide, Maria L
title: Development of a standardized data collection tool for evaluation and management of COVID-19
date: 2020-07-29
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa320
sha: 42e2a56aaaa4782cddf912d03b5d146bfad34179
doc_id: 889305
cord_uid: ftl4v9yz

BACKGROUND: SARS-CoV-2 virus is responsible for COVID-19, a disease that had not been previously described and for which clinicians need to rapidly adapt their daily practice. The novelty of SARS-CoV-2 produced significant gaps in harmonization of definitions, data collection, and outcome reporting to identify patients who would benefit from potential interventions. METHODS: We describe a multicenter collaboration to develop a comprehensive data collection tool for the evaluation and management of COVID-19 in hospitalized patients. The proposed tool was developed by a multidisciplinary working group of infectious disease physicians, intensivists, and infectious diseases/ Antimicrobial Stewardship Pharmacists. The working group regularly reviewed literature to select important patient characteristics, diagnostics, and outcomes for inclusion. The data collection tool consisted of spreadsheets developed to collect data from the electronic medical record and track the clinical course following treatments. RESULTS: Data collection focused on demographics and exposure epidemiology, prior medical history and medications, signs and symptoms, diagnostic test results, interventions, clinical outcomes and complications. During the pilot validation phase, there was <10% missing data for most domains and components. Team members noted improved efficiency and decision making by using the tool during interdisciplinary rounds. CONCLUSIONS: We present the development of a COVID-19 data collection tool and propose its use to effectively assemble harmonized data of hospitalized individuals with COVID-19. This tool can be used by clinicians, researchers, and quality improvement healthcare teams. It has the potential to facilitate interdisciplinary rounds, provide comparisons across different hospitalized populations, and adapt to emerging challenges posed by the pandemic.

Several patient characteristics have emerged as risk factors for severe illness and mortality. These include older age, male gender, smoking, black race, underlying co-morbidities (i.e. cardiovascular disease, diabetes, hypertension, chronic lung disease, cancer, chronic kidney disease, and obesity), symptomatology, and imaging findings at presentation to the hospital [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Additionally, certain laboratory findings have also been associated with poor outcomes (i.e. lymphopenia, high neutrophil-to lymphocyte ratio, elevated transaminases, elevated lactate dehydrogenase [LDH] , inflammatory biomarkers [C-reactive protein (CRP), ferritin, and D-dimer]), red blood cell distribution width (RDW), troponin, as well as indicators of acute kidney injury [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . However, these biomarkers require further validation to guide clinical practice in a novel pandemic 3, 15 .

Several agents have been used to treat patients during the current pandemic, based on in vitro antiviral/ anti-inflammatory activity or experience in other illnesses [25] [26] [27] . Some are FDA-approved products being used off-label and others are investigational drugs available from the manufacturer via compassionate use programs or as part of ongoing clinical trials. As of June 10th, 2020, no drugs have been licensed by the FDA for COVID-19 although remdesivir, an anti-viral with potentially broad activity, has received FDA emergency use authorization for use in COVID-19 26, 28 . However, results from the A c c e p t e d M a n u s c r i p t supporting clinical trials have only indicated efficacy in reducing illness duration and have not shown a statistically significant survival benefit 29, 30 . Limited literature 31 and anecdotal experience 32 suggests that timing of interventions and appropriate patient selection are important considerations. On April 21 st , the National Institutes of Health published national guidelines recommending that the use of therapeutic agents for the management of COVID-19 disease should be done in the context of a clinical trial 26 . As not all clinicians have access to clinical trials and knowledge evolves very rapidly, it is critical to collect systematic data on presentation, management, and clinical outcomes to provide feedback to frontline clinicians and to improve patient safety and quality of care 27 .

The large disease burden attributed to an emerging pathogen has led to a strong focus by the media, public health organizations, and the research community leading to an explosion of rapidly published scientific manuscripts of limited long-term analysis. Despite this, knowledge gaps remain and there is a need for harmonized definitions, data collection, and outcome reporting across many centers to identify those most likely to benefit from certain therapies, and those who are most likely to have poor outcomes 27 .

In the setting of the considerable unknowns faced daily by our clinical teams during the pandemic, we developed a system to study the presentation and outcomes of patients seen across our diverse practice sites in Miami, Florida, United States. In this study, we describe the development and pilot validation of a comprehensive data collection tool that was rapidly adopted in our hospital settings. The use of such a tool can harmonize systematic data collection within and between clinical sites to help guide clinical practice and research during this pandemic.

A c c e p t e d M a n u s c r i p t

This study was conducted in 3 large academic centers in Miami, FL, US. As of June 10, 2020, the counties served by the participating centers (Broward and Miami-Dade) reported 27,625 cases of COVID-19 33 .

Multiple factors could potentially contribute to poor outcomes in our setting: older average age, significant volume of visiting travelers, and high proportion of those who are economically disadvantaged or lack health insurance 34, 35 A c c e p t e d M a n u s c r i p t procalcitonin) with greater likelihood of severe/ critical COVID-19 [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , or in order to calculate intensive care unit (ICU) physiologic severity scores 37 . Anti-viral, anti-inflammatory, and supportive therapies included in the data collection tool were selected based on available literature and upon review of hospital protocols at our institution and other settings 20, 25, 27 . HIPAA-compliant spreadsheets were developed in order to track data trends and facilitate bi-weekly discussions. All elements included in the final data collection tool were discussed during the working group meetings, during international forums with clinicians from countries who encountered the pandemic early (Spain, Italy, China), and during interdisciplinary rounds with clinical providers-as this strategy has been shown to improve communication and foster agreement on the plan of care 38 . Factors were updated based on frequent forums and literature review until all members of the working group came to a mutual agreement.

Additionally, the working group decided to track important dates: illness onset, hospital admission, as well as beginning and end dates of ICU care, mechanical ventilation and other life support treatments, and anti-viral/ anti-inflammatory therapies. Working group members created a note template to evaluate those with confirmed or suspected COVID-19 using the above elements, and this was distributed to the infectious disease teams for use at their discretion.

The working group decided on standardized definitions of terms and format of data reporting to facilitate data analysis. Binary (i.e. 1= yes, 0= no) format was used unless additional complexity existed.

In these cases, either a limited set of result categories was established, or free-text format was used.

Care was taken to distinguish data that could not be obtained (left blank) versus normal/negative (recorded as "0"). If date of illness onset could not be ascertained, it was considered missing data (left blank). The data tool noted patients with chronic respiratory failure who were dependent on mechanical ventilation (yes/no) or supplemental oxygen at rest (yes/no).

Each vital sign was noted as normal ("0") or abnormal ("1") using the most severe value on day of admission:

A c c e p t e d M a n u s c r i p t The definitions for abnormal vital signs and COVID severity stage were based on early published natural history studies 3, 6, 16, 20 , which were recommended for disease staging in later guidelines 27 . However, we distinguished two different stages within the previously defined "critical" stage: Those with only respiratory failure were defined as "critical" and those with respiratory failure and failure of other organ systems requiring support were defined as "critical with MODS" (multiple organ dysfunction syndrome). The pilot validation phase was performed in the context of normal duties by ASP and the infectious disease team (fellows and/or staff physicians), using a convenience sample size. Data was entered and results shared with stakeholders (infectious disease team, intensivists, and ASP team) during interdisciplinary rounds. The clinical data collected during the pilot validation phase was input into secure clinical data management system at each site: SharePoint or RedCap®. The percentage of missing data was calculated by the number of patients in whom the data was missing by the total participants included in the pilot validation process. Missing data for diagnostic testing was calculated based on any data obtained prior to beginning any anti-viral or anti-inflammatory therapy. Missing data for interventions and clinical outcomes was calculated based on data available at date of discharge or death. Missing data for other outcomes was obtained after evaluation by the infectious disease team.

A c c e p t e d M a n u s c r i p t

The data collection tool was pilot tested with 200 patients admitted to one of the two participating centers over a 31-day period, and patient characteristics are described in Table 1 . The final data collection tool contained two main components with worksheets for infectious diseases and ASP teams (Supplemental Appendix; summarized in Table 2 ) and additional worksheets for definitions of abbreviations and terms, lab reference ranges, and data dictionary. The infectious diseases fellows and ASP found that the required data could be easily and efficiently collected, and all working group members were satisfied with its functionality. Stakeholders indicated that use of the tool improved decision making during interdisciplinary rounds by allowing rapid review of patient's clinical presentation, treatment, and clinical course. The major data domains, specific data, and results from data collection during the pilot validation phase is specified in Table 2 .

In both the development and pilot validation phase, scenarios arose that challenged our current framework of data reporting. When this occurred, a consensus decision was made within the working group in order to minimize reporting bias and maximize harmonization. Following this, relevant prior data underwent review and re-classification, if necessary, to ensure consistency.

After data extraction, we assessed the frequency of missing data ( Table 2) . Among demographic data, we had no missing data for gender or age and only 1.0% without race/ethnicity recorded. We had no missing data for epidemiologic exposures except 7.0% for history of foreign travel. All females of childbearing age had a point of care pregnancy test. Based on documentation available in the EMR of the participating institutions, there was <10% missing data on comorbidities of interest. Date of illness onset had 6.0% missing data, but presence of symptoms at admission was variably reported. There was no missing data for the most common symptoms (fever, cough, dyspnea), <20% missing data for other symptoms commonly associated with viral infections (e.g. sore throat, headache, nausea, diarrhea), and A c c e p t e d M a n u s c r i p t a greater percentage of missing data for uncommon symptoms (e.g. dysgeusia, anosmia)-which were often described during or after the development phase of our study. Data availability on most objective measures was excellent and there was <10% missing data except for a few specific tests: Respiratory viral PCR panel (46.0%: limited supply), CT scan (87.5%: limited use based on infection control concerns), and certain laboratory tests such as triglycerides (97.5%), procalcitonin (54.0%), and troponin (56.6%).

These lab tests were often not sent unless severe disease and potential association with severe COVID-19 was described during or after our development phase 19, 23, 41 .There was also significant missing data for interleukin-6 level and hepatitis B serologies, but these were obtained only in patients who were candidates for tocilizumab. There was no missing data regarding use of specific interventions, complications, or clinical outcomes. M a n u s c r i p t

We present the development of a COVID-19 data collection tool, which efficiently tracked comprehensive clinical data and provided up to date information to guide decision making in an era of rapidly evolving data. We propose its use to effectively collect harmonized data of individuals admitted to hospitals with confirmed or suspected SARS-CoV-2 infection 40 A c c e p t e d M a n u s c r i p t

The COVID-19 data collection tool can be used by clinicians, researchers, and quality control staff, and adapted to their own setting during this pandemic. It has the potential to enable comparisons across different hospitalized populations in the future, and to be rapidly adapted to the emerging challenges posed by the pandemic. In addition, it can be used easily and safely in settings with limited technology by using spreadsheets within secure data collection systems (RedCap®, SharePoint).

A few general observations in our study are worthy of discussion. The performance of the data tool during collection of data in all the major domains listed was enhanced by using the EMR but use of the tool was not dependent on review of EMR documentation. Daily interdisciplinary rounds featured presentation of new patients by the primary team who personally evaluated and interviewed the patient. Also, availability of data on diagnostic testing was dependent on the practice pattern of the primary medical team and infectious disease team. For example, the likelihood of missing data for diagnostic testing obtained prior to anti-viral/anti-inflammatory therapy was influenced by the adherence to recommendations for baseline laboratory testing by the primary medical team. In other cases, detailed information regarding uncommon or rare symptoms was not gathered or documented.

Often, there was low suspicion for COVID-19 and this information could not be obtained at the time of infectious disease evaluation due to patient condition. All these examples highlight the need for systematic data collection, and we recommend creating a site-specific note template to prompt clinicians to obtain data relevant for care of those with confirmed or suspected COVID-19.

There are a few opportunities for improvement that should be noted. First, the two centers in the pilot validation phase had different EMR systems, but we did not study differences in missing data or time needed to extract data between the two sites. Such comparison would have been confounded by differences in data collectors and is inconsistent with our proposed recommendation for others to adapt and optimize this tool locally. Thus, we cannot determine which EMR system had organization and functionality best suited to our tool. However, some EMR have downloadable data functionality and A c c e p t e d M a n u s c r i p t data tool organization should be optimized to receive output data in this manner, if available. Second, the scientific community should work toward consensus on how to report dynamic changes of certain biomarkers. This is important when data from multiple sites is combined for reporting since reference ranges and assays for lab tests may differ and may require normalizing procedures during analysis (e.g.

converting to percent or fold change from baseline or pre-treatment value). Third, we encountered few transplanted patients in the study. We believe a separate data collection tool should be developed and At this time, no intervention has been shown to be effective in a randomized controlled trial for the most relevant clinical endpoints: mortality, rate of progression to ARDS, and need for mechanical A c c e p t e d M a n u s c r i p t ventilation 26, 27, 29, 30 . Thus, current guidelines do not recommend any specific therapies and recommend use of available products only within the context of a clinical trial 26, 27 . Until more trial results are published, clinicians and hospital systems are faced with treating patients who are currently ill, leading to difficult decisions on the role of multiple unproven therapies and on which clinical trials to pursue.

We developed this data collection tool to track patient data relevant to the initial evaluation and ongoing management of hospitalized patients with COVID-19 infection. It can be adapted and applied to facilitate research involving cohort studies investigating patient characteristics associated with poor outcomes, specific therapies associated with clinical improvement, and appropriate timing or patient selection for therapy 45 . Thus, data collected through this tool can inform future clinical practice, improve patient safety and quality of care, and provide feedback for the design and conduct of trials evaluating the efficacy of the existing and novel therapies for COVID-19.

The work has been conducted under an IRB approved protocol (University of Miami protocol number 20200424). Based on the characteristics of the study (retrospective review of data obtained for purposes of clinical care and quality improvement), a waiver of informed consent was obtained from the IRB. M a n u s c r i p t M a n u s c r i p t 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

An interactive web-based dashboard to track COVID-19 in real time

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). WHO-China Jt Mission Coronavirus Dis

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Association of Obesity with Disease Severity among Patients with COVID-19. Obesity (Silver Spring)

COVID-19 and smoking: A systematic review of the evidence

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

He J; China Medical Treatment Expert Group for COVID-19. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China

Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A metaanalysis

Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

COVID-19) Treatment Guidelines. National Institutes of Health

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Epub ahead of print

US Food and Drug Administration

ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Florida's COVID-19 data and surveillance dashboard

United States census Bureau

World population review

Human Infection with 2019 Novel Coronavirus CDC

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

WHO R&D Blueprint novel Coronavirus: COVID-19 Therapeutic Trial Synopsis

National Notifiable Diseases Surveillance System: COVID-19 Interim Case Definition

HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Retrospective analysis of laboratory testing in 54 patients with severe-or criticaltype 2019 novel coronavirus pneumonia

Public health surveillance and data collection: general principles and impact on hemophilia care

US) Committee on the Consequences of Uninsurance. Care Without Coverage: Too Little, Too Late

Medical Center is conducting the REACT COVID-19: Real world Evidence for Anti-Cytokine Therapy in COVID-19, an international, multi-center, observational study

We would like to thank Dr. Paul Mariani (Lt. Col., United States Air Force) and Dr. Jonas Gonseth-Garcia (Pan-American Health Organization/ World Health Organization) for graciously offering to review the manuscript.The authors listed above do not have any professional or personal association that might pose a conflict of interest.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t M a n u s c r i p t ⁱⁱ Malignancy details: 11 solid, 9 hematologic, 1 patient with both; 4 on active chemotherapy * If none of the other exposure locations was noted, the patient was labeled community exposure, by default. ** Facility: residence in nursing home, assisted living, long term care facility, prison, homeless shelter. Note: visiting one of the previously mentioned places did not qualify and there was a separate category for ship. *** Health care worker was someone performing their job duties in patient care areas of the hospital. patients who had visited a hospital did not qualify A c c e p t e d M a n u s c r i p t **End of follow-up for diagnostic data is defined as last data available before death or discharge from the hospital. *** Assay: BioFire for Jackson Memorial Hospital, GenMark for University of Miami Hospital ****Significant missing data for interleukin-6 and hepatitis B serologies since these were only drawn in patients considered for Tocilizumab a Including respiratory support parameters: oxygen liters per minute, PEEP, FiO2, respiratory rate, tidal volume, prone positioning, or paralytic use. b Incorporates functional capacity and level of oxygenation and ventilation support needed to stabilize patient in the Emergency Department or initial level of care